,Canonical_Smiles,drug_name,drug_type,Label
0,C/C=C1/C[C@@H](C)[C@@](C)(O)C(=O)OCC2=CCN3CC[C@@H](OC1=O)[C@@H]23,senecionine,3A4-Substrate,negative
1,CC=CCC(C)C(=O)C1C(=O)NC(C(C)C)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,Valspodar,-,negative
2,COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2,Galantamine,2D6-Substrate,negative
3,CCC(N)Cc1ccc2c(c1)OCO2,BDB,2D6-Substrate,negative
4,COc1cc(Br)c2oc(C3CCNCC3)cc2c1,Brofaromine,2D6-Substrate,negative
5,CCC1(CC)C(=O)NC[C@@H](C)C1=O,Methyprylon,2D6-Substrate,negative
6,Cc1ccccc1,toluene,2E1-Substrate,negative
7,CO[C@@]1(NC(=O)CSCC#N)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21,Cefmetazole,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
8,FC(F)O[C@@H](Cl)C(F)(F)F,Isoflurane,2E1-Substrate,negative
9,NS(=O)(=O)Cc1noc2ccccc12,Zonisamide,-,negative
10,Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,Lamivudine,Solute_carrier_family_22_member_1-Substrate,negative
11,CCC1CC2CC3c4[nH]c5ccc(OC)cc5c4CCN(C2)C13,12_methoxy_ibogamine,2D6-Substrate,negative
12,Clc1ccc(CS[C@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,Sulconazole,2E1-Inhibitor,negative
13,CC(O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,Lisofylline,-,negative
14,CC(=O)Nc1ccccc1,Acetanilide,-,negative
15,C#CCN(C)Cc1ccccc1,Pargyline,2E1-Inhibitor,negative
16,COc1ccc([N+](=O)[O-])cc1,4_nitroanisole,2E1-Substrate,negative
17,COc1ccc2c(c1)c(CC(=O)NCCc1ccccc1)c(C)n2C(=O)c1ccc(Cl)cc1,indomethacin_phenethylamide,2D6-Substrate,negative
18,C[C@@H](O[C@@H]1OCCN(Cc2nc(=O)[nH][nH]2)[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,Aprepitant,P450_HFLA-Substrate,negative
19,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,Repaglinide,-,negative
20,CNC(=O)Oc1cccc2ccccc12,carbaryl,2E1-Substrate,negative
21,O=NN1CCCC1,N_nitroso_pyrrolidine,2E1-Substrate,negative
22,NC(=O)CC[C@H](N)C(=O)O,Levoglutamide,Neutral_amino_acid_transporter_B0-Substrate,negative
23,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,Digoxin,Multidrug_resistance_protein_1-Substrate,positive
24,CCCC(C)(COC(N)=O)COC(N)=O,Meprobamate,2E1-Substrate,negative
25,Cc1ccc(C(C)C)cc2c(C)ccc1-2,Guajazulen,1A2-Substrate,negative
26,Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C,Tiagabine,2D6-Substrate,negative
27,CC[S@@](=O)c1c(C#N)nn(-c2c(Cl)cc(C(F)(F)F)cc2Cl)c1N,ethiprole,3A4-Substrate,negative
28,Clc1ccccc1CN1CCc2sccc2C1,Ticlopidine,2E1-Inhibitor,negative
29,CC[C@]1(C)CC(=O)NC1=O,Ethosuximide,2E1-Substrate,negative
30,CON=CC1=CCCN(C)C1,Milameline,2D6-Substrate,negative
31,O=[P@@]1(N(CCCl)CCCl)OCCCN1CCCl,Trofosfamide,-,negative
32,CC(C)(N)Cc1ccccc1,Phentermine,2D6-Inhibitor,negative
33,Clc1ccc2nsnc2c1NC1=NCCN1,Tizanidine,1A2-Substrate,negative
34,CNC(=O)Oc1cccc2c1OC(C)(C)C2,carbofuran,2D6-Substrate,negative
35,C=CC1CC=CCC1,4_vinylcyclohexene,2E1-Substrate,negative
36,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,Metoclopramide,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inhibitor,negative
37,CC(C)CCON=O,Amyl Nitrite,GST-Substrate,negative
38,CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)[nH]c(N)nc21,Valaciclovir,Solute_carrier_family_15_member_2-Substrate,negative
39,CC(C)NNC(=O)c1ccncc1,Iproniazide,N_acetyltransferase-Inhibitor,negative
40,CC(=O)C[C@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,Warfarin,CP2CI-Substrate,negative
41,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,Docetaxel,Multidrug_resistance_protein_1-Substrate,positive
42,COc1ccc2c(c1)N(C[C@H](C)CN(C)C)c1ccccc1S2,Levomepromazine,2E1-Inhibitor,negative
43,Nc1nc2ccc(OC(F)(F)F)cc2s1,Riluzole,-,negative
44,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl,Lindane,N_acetyltransferase-Inducer,negative
45,COCCCOc1ccnc(CSc2nc3ccccc3[nH]2)c1C,rabeprazole_thioether,2E1-Substrate,negative
46,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@H]2CC[C@@H]1N2C,Cocaine,GST-Inducer,negative
47,CCC1(c2ccccc2)C(=O)NCNC1=O,Primidone,-,negative
48,Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1,flunarizine,2D6-Substrate,negative
49,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O,Lornoxicam,-,negative
50,O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1,Didanosine,Solute_carrier_family_15_member_1-Substrate,negative
51,CNCC[C@@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1,Fluoxetine,2E1-Substrate,negative
52,Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,Cladribine,ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
53,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2,Triazolam,P450_HFLA-Substrate,negative
54,CC(C)(C)NCC(O)COc1ccccc1C1CCCC1,Penbutolol,2D6-Substrate,negative
55,CCCCc1ncc(C=C(Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1,Eprosartan,-,negative
56,COc1ccccc1OC[C@H]1CNC(=O)O1,Mephenoxalone,Multidrug_and_toxin_extrusion_protein_1-Substrate,negative
57,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C,vicriviroc,2C9-Substrate,negative
58,C=CCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_12,3A4-Substrate,negative
59,CC(N)Cc1ccccc1,amphetamine,2D6-Substrate,negative
60,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1,Parecoxib,2D6-Inhibitor,negative
61,CCCO,Propanol,-,negative
62,CC(=O)N=c1sc(S(N)(=O)=O)nn1C,Methazolamide,2E1-Inhibitor,negative
63,CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,Capecitabine,2C9-Inhibitor,negative
64,O=C(CCCCCCC(=O)Nc1ccccc1)NO,Vorinostat,Methyltransferase-Inhibitor,negative
65,CCOC(=O)c1cncn1[C@@H](C)c1ccccc1,Etomidate,19A-Inhibitor,negative
66,CN[C@@]1(c2ccccc2Cl)CCCCC1=O,Ketamine,2D6-Substrate,negative
67,Nc1ccc(Cc2ccc(N)c(Cl)c2)cc1Cl,MOCA,3A4-Substrate,negative
68,CCCCCCNC(=N)NC(=N)N.Cl,Polihexanide,GST-Inhibitor,negative
69,COc1cc2nc(N3CCN(C(=O)[C@@H]4COc5ccccc5O4)CC3)nc(N)c2cc1OC,Doxazosin,2D6-Substrate,negative
70,Nc1nc([O-])c2c(n1)NCC(CNc1ccc(C(=O)NC(CCC(=O)[O-])C(=O)O)cc1)N2C=O.[Ca+2],Calcium folinate,-,negative
71,CC(C)(CO)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,w_OH_finasteride,3A4-Substrate,negative
72,CC(C)[C@]12CC(=O)[C@H](C)[C@H]1C2,alpha_thujone,3A4-Substrate,negative
73,COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c[nH]c2c1,BPR_0L075,2E1-Substrate,negative
74,CC[C@H](C)[C@H]1NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CCC(N)=O)NC1=O,Oxytocin,Solute_carrier_family_12_member_2-Inducer,negative
75,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@](C)(F)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Flurithromycin,-,negative
76,CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1,Proadifen,-,negative
77,C=CC#N,acrylonitrile,2E1-Substrate,negative
78,Cn1c(=O)[nH]c2ncn(C)c2c1=O,Paraxanthine,-,negative
79,O=c1ccc2nc3ccc(OCc4ccccc4)cc3oc-2c1,benzyl_oxy_resorufin,2D6-Substrate,negative
80,COc1ccc(CCN(C)CCC[C@](C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC,Gallopamil,-,negative
81,NC(N)=O,Carbamide,2E1-Inducer,negative
82,NNC(=O)c1ccncc1,Isoniazid,2E1-Inducer,negative
83,CN1CCN([C@@H](c2ccccc2)c2ccc(Cl)cc2)CC1,Chlorcyclizine,Multidrug_resistance_associated_protein_1-Substrate,negative
84,CC(O)(CC(=O)O)CC(=O)O,Meglutol,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
85,O=C(O)C=Cc1ccccc1,Bemiparin,SUL-Substrate,negative
86,Cc1cn[nH]c1,Fomepizole,2E1-Inhibitor,negative
87,CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12,Chloroquine,Multidrug_and_toxin_extrusion_protein_1-Inhibitor,negative
88,CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,Phenoxymethylpenicillin,3A4-Inducer,negative
89,CNCCCC1c2ccccc2C=Cc2ccccc21,Protriptyline,2D6-Substrate,negative
90,Clc1ccc([C@@H](Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1,Tioconazole,19A-Inhibitor,negative
91,CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl,Etizolam,2C19-Substrate,negative
92,CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,Pilocarpine,2E1-Substrate,negative
93,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,Valsartan,-,negative
94,Cc1ncc2c(c1O)CO[C@@H]2c1ccc(Cl)cc1,Cicletanine,UGT-Substrate,negative
95,CCNc1nc(Cl)nc(NC(C)(C)C)n1,terbutylazine,2C19-Substrate,negative
96,Clc1ccc(CO[C@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,Miconazole,19A-Inhibitor,negative
97,CC12CCC3C(CCC4=CC(=O)C=CC43C)C1CCC(=O)O2,Testolactone,-,negative
98,c1ccc(C2(N3CCCCC3)CCCCC2)cc1,Phencyclidine,-,negative
99,OCCc1ccccc1Nc1c(Cl)cccc1Cl,diclofenac_deriv_2,2C19-Substrate,negative
100,N.N.O=C1O[Pt]OC(=O)C12CCC2,Carboplatin,3A4-Inducer,negative
101,CNCCN1C(=O)[C@H](OC(C)=O)[C@H](c2ccc(OC)cc2)Sc2ccccc21,N_desmethyl_diltiazem,3A4-Substrate,negative
102,COc1ccc2cc(C#N)c(=O)oc2c1,7_methoxy_3_cyano_coumarin,2E1-Substrate,negative
103,O=C1CC(=O)N(c2ccccc2)c2cc(Cl)ccc2N1,N_desmethyl_clobazapam,2C19-Substrate,negative
104,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1,Methylphenidate,-,negative
105,O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21,Atovaquone,-,negative
106,CCC[C@@H](C)[C@@]1(CC)C(=O)N=C(S)NC1=O,Thiopental,2E1-Inhibitor,negative
107,C=CC(=C)C,isoprene,2E1-Substrate,negative
108,CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,Glimepiride,-,negative
109,CCC1NC(=O)C(NC(=O)c2ncccc2O)C(C)OC(=O)C(c2ccccc2)NC(=O)C2CC(=O)C(CSC3CN4CCC3CC4)CN2C(=O)C(Cc2ccc(N(C)C)cc2)N(C)C(=O)C2CCCN2C1=O,Quinupristin,-,negative
110,COc1ccccc1OCCNC[C@H](O)COc1cccc2[nH]c3ccccc3c12,carvedilol_S,2D6-Substrate,negative
111,CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C,Pentazocine,2D6-Substrate,negative
112,O=[N+]([O-])c1cncn1CCN1CCOCC1,Nimorazole,-,negative
113,OC(CNCC(F)(F)F)COc1cccc2ccccc12,N_trifluoro_ethyl_desisopropyl_propranolol,2D6-Substrate,negative
114,COc1ccc(CCN(C)CCC[C@@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,Verapamil,Multidrug_resistance_protein_1-Substrate,positive
115,CCCc1nc(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)[nH]n12,Vardenafil,HLp2-Substrate,negative
116,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C1C,Everolimus,-,negative
117,CCN[C@H](C)Cc1ccc2c(c1)OCO2,MDE_R,2E1-Substrate,negative
118,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,Azacitidine,Methyltransferase-Inhibitor,negative
119,COc1ccc2[nH]cc(CCN(C(C)C)C(C)C)c2c1,foxy,2D6-Substrate,negative
120,Cc1cc(C)c(NC(=O)CN(CC(=O)O)CC(=O)O)c(C)c1Br,Technetium (99mTc) Mebrofenin,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
121,C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)C(=NOCC(=O)O)c3csc(N)n3)[C@H]2SC1,Cefixime,Solute_carrier_family_15_member_1-Substrate,negative
122,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,Flurbiprofen,-,negative
123,NC(=O)c1ccccc1O,Salicylamide,1B1-Inhibitor,negative
124,CC(=O)Nc1ccc(O)cc1,Paracetamol,2E1-Inducer,negative
125,CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1,Rivastigmine,2D6-Inhibitor,negative
126,Cc1ccc(C(=O)[C@H](C)CN2CCCCC2)cc1,Tolperisone,2D6-Substrate,negative
127,CCOc1ccc2c(C(F)(F)F)cc(=O)oc2c1,7_ethoxy_4_trifluoro_methyl_coumarin,2E1-Substrate,negative
128,COc1ccc2[nH]c3c([N+](=O)[O-])ccc4c3c(nn4CCCN(C)C)c2c1,pyrazolo_acridine,1A2-Substrate,negative
129,CCC1(C)CC(OC(=O)CSc2n[nH]c(N)n2)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O,Azamulin,-,negative
130,Nc1nc2[nH]cnc2c(=S)[nH]1,Tioguanine,Solute_carrier_family_28_member_3-Substrate,negative
131,COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC,Vernakalant,2D6-Substrate,negative
132,CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1,Talinolol,Multidrug_resistance_protein_1-Substrate,positive
133,COc1ccc(OC)c([C@@H](O)[C@@H](C)N)c1,Methoxamine,Solute_carrier_family_12_member_2-Inducer,negative
134,Cc1onc(NS(=O)(=O)c2ccc(N)cc2)c1C,Sulfatroxazole,-,negative
135,COCc1c(C(=O)OC(C)C)ncc2[nH]c3ccc(OCc4ccccc4)cc3c12,Abecarnil,-,negative
136,NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O,Chlorothiazide,Solute_carrier_family_22_member_8-Substrate,negative
137,CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,Terconazole,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
138,NC(=O)NN=Cc1ccc([N+](=O)[O-])o1,Nitrofural,2D6-Substrate,negative
139,O=C(NC[C@@H]1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F,Flecainide,2D6-Substrate,negative
140,CN(C)C(=S)SSC(=S)N(C)C,Thiram,2E1-Substrate,negative
141,CCC[C@@](C)(COC(N)=O)COC(=O)NC(C)C,Carisoprodol,-,negative
142,CC(=O)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C,Pregnenolone,2D6-Substrate,negative
143,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Gemcitabine,Multidrug_resistance_associated_protein_5-Inducer,negative
144,C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,Fulvestrant,3A4-Substrate,negative
145,C=C1CC[C@@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O,Calcifediol,24A-Substrate,negative
146,COc1ccc2c3c1O[C@H]1C(OC(C)=O)=CC[C@@H]4[C@@H](C2)N(C)CC[C@@]341,Thebacon,2D6-Substrate,negative
147,CCc1ccc([C@@H](C)CCc2ccc([N+](C)(C)C)cc2)cc1,Colestyramine,Sodiumbile_acid_cotransporter-Inducer,negative
148,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,Posaconazole,UGT-Substrate,negative
149,CC(NCC(O)COc1cccc2ccccc12)C(F)F,difluoro_propranolol,2D6-Substrate,negative
150,N=C(N)NC[C@H]1COc2ccccc2O1,Guanoxan,2D6-Substrate,negative
151,O=C1CN(N=Cc2ccc([N+](=O)[O-])o2)C(=O)N1,Nitrofurantoin,ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
152,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1,Tirilazad,-,negative
153,ClC=C(Cl)Cl,Trichloroethylene,2E1-Substrate,negative
154,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,buprenorphine,2C8-Substrate,negative
155,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1c1cccc(Cl)c1Cl,Felodipine,P450_HFLA-Substrate,negative
156,C[C@@H]1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1,Temafloxacin,1A2-Substrate,negative
157,CO[C@H]1C=CO[C@]2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,Rifamycin,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
158,N[C@H]1C[C@@H]1c1ccccc1,Tranylcypromine,2E1-Inhibitor,negative
159,Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1,Triamterene,1A2-Inhibitor,negative
160,CCCC(=O)Nc1ccc(OC[C@@H](O)CNC(C)C)c(C(C)=O)c1,Acebutolol,2D6-Inhibitor,negative
161,C/C=C/C,trans_2_butene,2E1-Substrate,negative
162,CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1,Azatadine,-,negative
163,CC(C)O,Isopropanol,2E1-Inducer,negative
164,CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1,Atenolol,3A4-Substrate,negative
165,COc1ccc2c(C(F)(F)F)cc(=O)oc2c1,7_methoxy_4_trifluoro_methyl_coumarin,2E1-Substrate,negative
166,Cc1ccc(O)cc1,p_cresol,2E1-Substrate,negative
167,CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12,Abiraterone,-,negative
168,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,Fluphenazine,2E1-Inhibitor,negative
169,CNC(=S)Oc1cc(C)c(SC)c(C)c1,methiocarb,2D6-Substrate,negative
170,CN1CCCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,Homochlorcyclizine,-,negative
171,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,Timolol,2D6-Substrate,negative
172,CCN(CC)C(=O)NC1CC2c3cccc4[nH]cc(c34)CC2N(C)C1,Terguride,2D6-Substrate,negative
173,Clc1ccc([C@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1,Isoconazole,19A-Inhibitor,negative
174,CCOC(=O)[C@@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,Enalapril,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
175,CCCC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@@H]2CO[P@@](=O)(O)O[C@H]2[C@H]1OC(=O)CCC,Bucladesine,19A-Inducer,negative
176,CCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_4,3A4-Substrate,negative
177,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O,Phenylbutazone,-,negative
178,C[C@H](N)Cc1ccccc1,Dexamfetamine,2D6-Inhibitor,negative
179,COCCCCC(=NOCCN)c1ccc(C(F)(F)F)cc1,Fluvoxamine,2E1-Substrate,negative
180,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@@](C)(C(=O)O)CC[C@]3(C)CC[C@]21C,Enoxolone,Canalicular_multispecific_organic_anion_transporter_1-Inhibitor,negative
181,CCCCC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1,Propiverine,3A4-Inhibitor,negative
182,CN1CCN2c3ccccc3Cc3ccccc3[C@@H]2C1,mianserin_R,2D6-Substrate,negative
183,CC(C)(C)NC[C@H](O)COc1cccc2c1CCC(=O)N2,Carteolol,2D6-Inhibitor,negative
184,CS(C)=O,Dimethyl Sulfoxide,2D6-Inhibitor,negative
185,c1ccccc1,Benzene,-,negative
186,CN(C)c1ccc(C2CC3(C)C(CCC3(O)C=CCO)C3CCC4=CC(=O)CCC4=C23)cc1,Lilopristone,-,negative
187,Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1,Torasemide,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
188,CC(C)(C(=O)c1cccnc1)c1cccnc1,Metyrapone,2E1-Inhibitor,negative
189,CC(C)(C)N1CCC(c2ccccc2)(c2ccccc2)CC1,Budipine,2D6-Inhibitor,negative
190,Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C,Sulfamoxole,-,negative
191,O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1,Rebamipide,-,negative
192,CC(C)(C)C(O)C=Cc1ccc2c(c1)OCO2,Stiripentol,-,negative
193,CCC[N@@+]12[C@H]3C[C@@]45c6ccccc6N(C)[C@H]4[C@@H]1C[C@H]([C@@H]3[C@H]5O)[C@H](CC)[C@H]2O,Prajmaline,2D6-Substrate,negative
194,CCC[C@H](N[C@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,Perindopril,GST-Inhibitor,negative
195,Cc1cc(NC(=O)NC(=O)c2ccccc2N(C)C)ccc1Oc1ncc(Br)cn1,benzoyl_phenyl_urea,2D6-Substrate,negative
196,Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,Dicloxacillin,Multidrug_resistance_protein_1-Substrate,positive
197,CNCCCN1c2ccccc2CCc2ccccc21,Desipramine,2E1-Inhibitor,negative
198,Cc1cc(O)cc(C)c1Cl,Chloroxylenol,2E1-Substrate,negative
199,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)C1=O,9_alpha_fluoro_androstadienedione,3A4-Substrate,negative
200,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,Nelfinavir,Multidrug_resistance_protein_1-Substrate,positive
201,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C,Ciclesonide,3A4-Substrate,negative
202,Cc1c2ccncc2c(C)c2c1[nH]c1ccccc12,ellipticine,2D6-Substrate,negative
203,CC(C)n1c(C=C[C@H](O)C[C@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,Fluvastatin,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
204,O=C1C(CCSc2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1,sulfinpyrazone_sulfide,2C9-Substrate,negative
205,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,Aripiprazole,P450_HFLA-Substrate,negative
206,CC=CC[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,Ciclosporin,Multidrug_resistance_protein_1-Substrate,positive
207,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,Escitalopram,2D6-Substrate,negative
208,Cc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,dimemorfan,2D6-Substrate,negative
209,CC(C)[C@]12CC(=O)[C@@H](C)[C@H]1C2,beta_thujone,3A4-Substrate,negative
210,Nc1cc(N2CCCCC2)nc(N)[n+]1[O-],Minoxidil,SUL-Substrate,negative
211,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,Tretinoin,Solute_carrier_family_28_member_3-Inducer,negative
212,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,MK_0457_tozasertib,2D6-Substrate,negative
213,CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2,Moracizine,-,negative
214,Cc1ccccc1C,xylene_ortho,2E1-Substrate,negative
215,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1,Clindamycin,-,negative
216,COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1,iloperidone,2D6-Substrate,negative
217,O[C@@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@H]1CCCCN1,Mefloquine,19A-Inhibitor,negative
218,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@@H]4[C@H](CC[C@]3(O)C2)[C@@]2(O)CC[C@H](C3=CC(=O)OC3)[C@@]2(C)C[C@H]4O)[C@H](O)[C@H](O)[C@H]1O,G-strophanthin,Multidrug_resistance_associated_protein_1-Inducer,negative
219,CN(CC(=O)O)C(=N)NP(=O)(O)O,Fosfocreatine,Methyltransferase-Inhibitor,negative
220,NC[C@@H](O)c1ccc(O)c(O)c1,Norepinephrine,19A-Inhibitor,negative
221,COc1ccc(-c2cc(=O)c3c(O)c(OC)c(O)cc3o2)cc1OC,eupatilin,2E1-Substrate,negative
222,CCN(CCO)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12,Hydroxychloroquine,2D6-Inhibitor,negative
223,Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1,Sulfadimidine,-,negative
224,Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,Leflunomide,-,negative
225,NC(=O)N1c2ccccc2CC(=O)c2ccccc21,Oxcarbazepine,-,negative
226,C=CCc1ccc2c(c1)OCO2,safrole,2E1-Substrate,negative
227,Cc1ncc(CO)c(CO)c1O,Pyridoxine (vit B6),Methyltransferase-Inhibitor,negative
228,CCCN(CCC)N=O,NN_dipropyl_nitrosoamine,2E1-Substrate,negative
